|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Loxo_Oncology
gptkb:Im_Clone_Systems
gptkb:Avid_Radiopharmaceuticals
gptkb:Lilly_ICOS
|
|
gptkbp:awards
|
Best Places to Work
Fortune 500 company
World's Most Admired Companies
|
|
gptkbp:ceo
|
gptkb:David_A._Ricks
gptkb:2017
|
|
gptkbp:clinical_trial
|
gptkb:diabetes
gptkb:Oncology
gptkb:neurodegenerative_diseases
ongoing
conducts numerous clinical trials
|
|
gptkbp:community_engagement
|
partnerships with educational institutions
provides scholarships
supports local health initiatives
volunteer programs for employees
|
|
gptkbp:conducts_research_on
|
gptkb:Daniel_Skovronsky
gptkb:Dr._Daniel_Skovronsky
|
|
gptkbp:employees
|
over 35,000
35,000
|
|
gptkbp:focus_area
|
gptkb:diabetes
oncology
immunology
|
|
gptkbp:founded
|
1876
|
|
gptkbp:founder
|
gptkb:Eli_Lilly
|
|
gptkbp:global_presence
|
over 125 countries
operates in over 120 countries
|
|
gptkbp:has_research_center
|
multiple worldwide
|
|
gptkbp:headcount
|
approximately 38,000 (2021)
|
|
gptkbp:headquarters
|
gptkb:Indianapolis
gptkb:Indianapolis,_Indiana
gptkb:One_Lilly_Corporate_Center
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Eli Lilly and Company
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:invention
|
over 10,000
over 1000
|
|
gptkbp:market
|
global
|
|
gptkbp:market_cap
|
approximately $200 billion (2021)
$150 billion (2021)
|
|
gptkbp:partnership
|
gptkb:Incyte_Corporation
gptkb:Astra_Zeneca
gptkb:Boehringer_Ingelheim
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:partnerships
|
gptkb:Boehringer_Ingelheim
gptkb:Pfizer
gptkb:Amgen
various universities
|
|
gptkbp:philanthropy
|
gptkb:Lilly_Foundation
|
|
gptkbp:products
|
gptkb:diabetes
gptkb:Cymbalta
gptkb:Humalog
gptkb:Trulicity
antidepressants
oncology drugs
|
|
gptkbp:related_products
|
gptkb:Cymbalta
gptkb:Emgality
gptkb:Forteo
gptkb:Humalog
gptkb:Lilly's_COVID-19_antibody_therapy
gptkb:Olumiant
gptkb:Taltz
gptkb:Trulicity
gptkb:Verzenio
gptkb:Zyprexa
gptkb:Reyvow
gptkb:Tirzepatide
gptkb:Basaglar
gptkb:Alimta
gptkb:Lilly's_COVID-19_antibody_treatment
|
|
gptkbp:research_and_development
|
$6.5 billion (2020)
|
|
gptkbp:research_focus
|
gptkb:diabetes
gptkb:Oncology
gptkb:neurodegenerative_diseases
autoimmune diseases
neuroscience
immunology
|
|
gptkbp:revenue
|
$28.5 billion (2020)
$24.5 billion (2020)
|
|
gptkbp:stock_exchange
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:stock_symbol
|
gptkb:LLY
|
|
gptkbp:subsidiaries
|
gptkb:Elanco_Animal_Health
gptkb:Lilly_USA,_LLC
|
|
gptkbp:subsidiary
|
gptkb:Elanco_Animal_Health
|
|
gptkbp:sustainability_efforts
|
water conservation initiatives
investing in renewable energy
waste reduction programs
committed to reducing carbon footprint
|
|
gptkbp:sustainability_initiatives
|
community engagement
diversity and inclusion
diversity and inclusion programs
community engagement programs
supply chain sustainability
environmental responsibility
patient access initiatives
environmental responsibility programs
patient access programs
supply chain responsibility
|
|
gptkbp:traded_on
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:type
|
gptkb:pharmaceuticals
|
|
gptkbp:website
|
www.lilly.com
|
|
gptkbp:bfsParent
|
gptkb:Pfizer
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:urban_park
|
|
gptkbp:bfsLayer
|
4
|